Interdisziplinäre S3-Leitlinie zur „Prävention und Therapie der
                    Adipositas“ der Deutschen Adipositas-Gesellschaft (DAG) – Überblick über die
                    Empfehlungen zu den Themen „Stigmatisierung“, „Diagnostik“ und
                    „Therapie“

Martina de Zwaan; Hans Hauner; Christina Holzapfel; Stefan Engeli; Leitlinienkoordinator*in, stellvertretend für alle Arbeitsgruppenmitglieder:; Verfasser des kondensierten Textes (Schriftleiter der Zeitschrift Adipositas):

doi:10.1055/a-2552-3990

Adipositas - Ursachen, Folgeerkrankungen, Therapie, Inhaltsverzeichnis

Adipositas - Ursachen, Folgeerkrankungen, Therapie 2025; 19(02): 84-109
DOI: 10.1055/a-2552-3990

Leitlinie

Interdisziplinäre S3-Leitlinie zur „Prävention und Therapie der Adipositas“ der Deutschen Adipositas-Gesellschaft (DAG) – Überblick über die Empfehlungen zu den Themen „Stigmatisierung“, „Diagnostik“ und „Therapie“

Leitlinienkoordinator*in, stellvertretend für alle Arbeitsgruppenmitglieder:,

Martina de Zwaan

¹Klinik für Psychosomatik und Psychotherapie, Medizinische Hochschule Hannover, Hannover, Deutschland

,

Hans Hauner

¹Klinik für Psychosomatik und Psychotherapie, Medizinische Hochschule Hannover, Hannover, Deutschland

,

Verfasser des kondensierten Textes (Schriftleiter der Zeitschrift Adipositas):,

Christina Holzapfel

²Institut für Ernährungsmedizin, School of Medicine and Health, Technische Universität München, München, Deutschland

³Fachbereich Oecotrophologie, Hochschule Fulda, Fulda, Deutschland

,

Stefan Engeli

⁴Abteilung für Klinische Pharmakologie, Institut für Pharmakologie am Center of Drug Absorption and Transport (C_DAT), Universitätsmedizin Greifswald, Greifswald, Deutschland

› Institutsangaben

Abstract

Zusammenfassung

Dieser Artikel fasst einen wesentlichen Teil der Empfehlungen der im Herbst 2024 durch die Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) zertifizierte S3-Leitlinie zur „Prävention und Behandlung der Adipositas“ der Deutschen Adipositas-Gesellschaft (DAG) zusammen. Aus Platzgründen ausgeklammert werden die Kapitel „Definition und medizinische Einordnung von Übergewicht und Adipositas“, da die Leitlinie hier keine Empfehlungen gibt, und „Prävention“, da die Arbeitsgruppe eigene Publikationen zum Thema plant. Hier behandelt werden die Kapitel „Stigmatisierung“ (neu in der Leitlinie enthalten), „Diagnostik“ und „Therapie“, wobei hier auch neue Bereiche wie E-Health inkludiert sind. Hinsichtlich der Ernährungstherapie gibt es heute eine Vielfalt evidenzbasierter Ansätze, die eine stärker personalisierte Therapie erlauben. Die adjuvante Pharmakotherapie hat einen deutlich größeren Stellenwert als in der vorhergehenden Version der Leitlinie, da mit den Glucagon-like Peptide-1 (GLP-1)-basierten Wirkstoffen inzwischen sehr wirksame Ansätze nicht nur zur Gewichtsreduktion, sondern auch zur Besserung von Begleit- und Folgeerkrankungen vorliegen. Für das Kapitel „Adipositaschirurgie“ der Vorgängerversion der Leitlinie wurde wegen der begrenzten Resourcen auf eine Literaturrecherche verzichtet und stattdessen auf die „Leitlinie zur Adipositaschirurgie“ der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV) aus dem Jahr 2018 verwiesen, deren baldige Aktualisierung beschlossen ist. Beide Leitlinien werden sich zukünftig ergänzen.

Abstract

This article summarizes most of the recommendations of the current German evidence-based guideline (certified by the Association of Scientific Medical Societies in Germany, AWMF) on the “Prevention and Treatment of Obesity”, which was put together by the German Association for the Study of Obesity. For the sake of space, we left out the chapter on “Definitions”, because no recommendations are stated there. A summary of the chapter on “Prevention“, will be separately published by the respective working group. We focus on the chapters on “Stigmatization” (new in this guideline version), “Diagnostics”, and “Therapy” which is supplemented by a discussion on E-Health approaches. Considering dietary therapy, many evidence-based approaches are available nowadays, allowing more personalized treatment considerations. Pharmacotherapy as an adjunct approach has become much more important since the last version of the guideline because Glucagon-like Peptide-1 (GLP-1)-based medicines not only improved the amount of weight loss but have also shown beneficial effects on several comorbidities of obesity. The last version of the guideline also included a chapter on “Obesity Surgery”. This chapter was left unchanged, because a seperate guideline from the German Society for General and Visceral Surgery on that issue exists and will be updated rather soon. In the future both guidelines will be used back-to-back.

Interdisciplinary S3 Guideline on “Prevention and Treatment of Obesity” by the German Association for the Study of Obesity (DAG) – Overview of the recommendations on the topics “Stigmatization,” “Diagnostics,” and “Therapy”

Schlüsselwörter

Übergewicht - Adipositas - evidenzbasierte Leitlinie - Stigmatisierung - Ernährungstherapie - Pharmakotherapie

Keywords

overweight - obesity - evidence-based guideline - stigmatization - dietary therapy - pharmacotherapy

Volltext

Referenzen

Literatur
1 Deutsche Adipositas-Gesellschaft (DAG) e.V. S3-Leitlinie Adipositas – Prävention und Therapie. Version 5.0 Oktober 2024. Verfügbar unter https://register.awmf.org/de/leitlinien/detail/050-001
2 Alimoradi Z. et al. Weight-related stigma and psychological distress: A systematic review and meta-analysis. Clin Nutr 2020; 39 p 2001-2013
3 Albano G. et al. Interpersonal difficulties in obesity: A systematic review and meta-analysis to inform a rejection sensitivity-based model. Neurosc Biobehav Rev 2019; 107: 846-861
4 Emmer C, Bosnjak M, Mata J. The association between weight stigma and mental health: A meta-analysis. Obes Rev. 2019 21.
5 Lee M, Ata RN, Brannick MT. Malleability of weight-biased attitudes and beliefs: A meta-analysis of weight bias reduction interventions. Body Image 2014; 11: 251-259
6 Cameron AJ, Magliano DJ, Söderberg S. A systematic review of the impact of including both waist and hip circumference in risk models for cardiovascular diseases, diabetes and mortality. Obes Rev 2012; 14: 86-94
7 de Hollander EL. et al. The association between waist circumference and risk of mortality considering body mass index in 65- to 74-year-olds: a meta-analysis of 29 cohorts involving more than 58 000 elderly persons. Int J Epidemiol 2012; 41: 805-817
8 Becroft L. et al. Validity of multi-frequency bioelectric impedance methods to measure body composition in obese patients: a systematic review. Int J Obes 2018; 43: 1497-1507
9 Chang S-H. et al. A systematic review of body fat distribution and mortality in older people. Maturitas 2012; 72: 175-191
10 Menotti A. et al. Indexes of Obesity and All-Causes Mortality in Italian Epidemiologic Data. Prev Med 1993; 22: 293-303
11 Atlantis E. et al. Usefulness of the Edmonton Obesity Staging System for stratifying the presence and severity of weight-related health problems in clinical and community settings: A rapid review of observational studies. Obes Rev. 2020 21.
12 Ejima K, Xavier NA, Mehta T. Comparing the Ability of Two Comprehensive Clinical Staging Systems to Predict Mortality: EOSS and CMDS. Obesity 2020; 28: 353-361
13 Manasse SM. et al. Executive functioning in overweight individuals with and without loss-of-control eating. Eur Eat Disord Rev 2014; 22: 373-377
14 Palavras MA. et al. The Efficacy of Psychological Therapies in Reducing Weight and Binge Eating in People with Bulimia Nervosa and Binge Eating Disorder Who Are Overweight or Obese-A Critical Synthesis and Meta-Analyses. Nutrients 2017; 9: 299
15 Somerset SM, Graham L, Markwell K. Depression scores predict adherence in a dietary weight loss intervention trial. Clin Nutr 2011; 30: 593-598
16 Lammert A. et al. Performance of the 1 mg dexamethasone suppression test in patients with severe obesity. Obesity (Silver Spring) 2016; 24: 850-855
17 Yavuz DG. et al. Assessment of 1 mg Dexamethasone Suppression Test in Patients with Obesity Before Bariatric Surgery. Obes Surg 2020; 30: 4981-4985
18 Assmann G, Cullen P, Schulte H. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation 2002; 105: 310-315
19 Assmann G. et al. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest 2007; 37: 925-932
20 Conroy RM. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003
21 Zhao L. et al. Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis. Chin Med J 2020; 133: 982-993
22 Institute for Evidence-Based Healthcare, BondUniversity. Evidence synthesis to support the development of guideline for cardiovascular disease risk, 2021: https://d35rj4ptypp2hd.cloudfront.net/pdf/7.-Report-1-Evidence-Synthesis-Report-Bond-University.pdf
23 Parhofer KG, Laufs U. The Diagnosis and Treatment of Hypertriglyceridemia. Dtsch Arztebl Int 2019; 116: 825-832
24 DEGAM. AWMF S3-Leitlinie Hausärztliche Risikoberatung zur kardiovaskulären Prävention.
25 Hemingway H. et al. Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS medicine 2010; 7: e1000286-e1000286
26 Schwarzer R. et al. Prognostische Wertigkeit und klinische Effektivität des hochsensitiven C-reaktiven Proteins als Marker in der Primärprävention der koronaren Herzkrankheit. Z Evid Fortbild Qual Gesundhwes 2009; 103: 319-329
27 Schnell-Inderst P. et al. Stellenwert des hochsensitiven C-reaktiven Proteins (hs-CRP) als Marker für Herzinfarktgefährdung. GMS Health Technol Assess 2009; 5: Doc06
28 Si S. et al. Effectiveness of general practice-based health checks: a systematic review and meta-analysis. Br J Gen Pract 2014; 64: e47-e53
29 Lee J. et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int 2021; 41: 261-270
30 Wangler J, Jansky M. [Clarification of increased liver values in primary care – Findings from a series of studies from a general practitioner and specialist perspective]. Z Gastroenterol 2023; 61: 381-389
31 Scottish Intercollegiate Guidelines Network (SIGN). Management of Obesity. A national clinical guideline. 2010 June 10, 2022]; Available from https://www.sign.ac.uk/assets/sign115.pdf
32 Wu T. et al. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obes Rev 2009; 10: 313-323
33 Södlerlund A, Fischer A, Johansson T. Physical activity, diet and behaviour modification in the treatment of overweight and obese adults: a systematic review. Perspect Public Health 2009; 129: 132-142
34 Witham MD, Avenell A. Interventions to achieve long-term weight loss in obese older people: a systematic review and meta-analysis. Age Ageing 2010; 39: 176-184
35 Johns DJ. et al. Diet or exercise interventions vs combined behavioral weight management programs: a systematic review and meta-analysis of direct comparisons. J Acad Nutr Diet 2014; 114: 1557-1568
36 Ge L. et al. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ 2020; 369: m696
37 Singh N, Stewart RAH, Benatar JR. Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials. BMJ open 2019; 9: e029966-e029966
38 Hartmann-Boyce J. et al. Behavioural weight management programmes for adults assessed by trials conducted in everyday contexts: systematic review and meta-analysis. Obes Rev 2014; 15: 920-932
39 Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ (Clinical research ed.) 2020; 370: m3095-m3095
40 Astbury NM. et al. A systematic review and meta-analysis of the effectiveness of meal replacements for weight loss. Obes Rev 2019; 20: 569-587
41 Harris L. et al. Intermittent fasting interventions for treatment of overweight and obesity in adults. JBI Database System Rev Implement Rep 2018; 16: 507-547
42 Roman YM. et al. Effects of intermittent versus continuous dieting on weight and body composition in obese and overweight people: a systematic review and meta-analysis of randomized controlled trials. Int J Obes 2018; 43: 2017-2027
43 Noronha JC. et al. The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diab Care 2019; 42: 767-776
44 Parretti HM. et al. Clinical effectiveness of very-low-energy diets in the management of weight loss: a systematic review and meta-analysis of randomized controlled trials. Obes Rev 2016; 17: 225-234
45 Muscogiuri G. et al. European Guidelines for Obesity Management in Adults with a Very Low-Calorie Ketogenic Diet: A Systematic Review and Meta-Analysis. Obes Facts 2021; 14: 222-245
46 Donnelly JE. et al. Appropriate Physical Activity Intervention Strategies for Weight Loss and Prevention of Weight Regain for Adults. Med Sci Sports Exerc 2009; 41: 459-471
47 Wewege M. et al. The effects of high-intensity interval training vs. moderate-intensity continuous training on body composition in overweight and obese adults: a systematic review and meta-analysis. Obes Rev 2017; 18: 635-646
48 Anderson JW. et al. Effect of a behavioral/nutritional intervention program on weight loss in obese adults: a randomized controlled trial. Postgrad Med 2011; 123: 205-213
49 Rodriguez-Hernandez H. et al. Adding cognitive behavioural treatment to either low-carbohydrate or low-fat diets: differential short-term effects. Br J Nutr 2009; 102: 1847-1853
50 Acharya SD. et al. Using a personal digital assistant for self-monitoring influences diet quality in comparison to a standard paper record among overweight/obese adults. J Am Diet Assoc 2011; 111: 583-588
51 Burke LE. et al. The effect of electronic self-monitoring on weight loss and dietary intake: a randomized behavioral weight loss trial. Obesity (Silver Spring) 2011; 19: 338-344
52 Wing RR. et al. Improving weight loss outcomes of community interventions by incorporating behavioral strategies. Am J Public Health 2010; 100: 2513-2519
53 Burke LE, Wang J, Sevick MA. Self-monitoring in weight loss: a systematic review of the literature. J Am Diet Assoc 2011; 111: 92-102
54 Teufel M. et al. Psychotherapie und Adipositas. Der Nervenarzt 2011; 82: 1133-1139
55 Khera R. et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016; 315: 2424-2434
56 Khera R. et al. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. Gastroenterology 2018; 154: 1309-1319.e7
57 Siebenhofer A. et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev 2021; 1: Cd007654
58 Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol 2020; 13: 53-64
59 Rubino D. et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021; 325: 1414-1425
60 Jastreboff AM. et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022; 387: 205-216
61 Yen HY, Chiu HL. The effectiveness of wearable technologies as physical activity interventions in weight control: A systematic review and meta-analysis of randomized controlled trials. Obes Rev 2019; 20: 1485-1493
62 Cavero-Redondo I. et al. Effect of Behavioral Weight Management Interventions Using Lifestyle mHealth Self-Monitoring on Weight Loss: A Systematic Review and Meta-Analysis. Nutrients 2020; 12
63 Beleigoli A. et al. Personalized Web-Based Weight Loss Behavior Change Program With and Without Dietitian Online Coaching for Adults With Overweight and Obesity: Randomized Controlled Trial. J Med Internet Res 2020; 22: e17494
64 Huang JW, Lin YY, Wu NY. The effectiveness of telemedicine on body mass index: A systematic review and meta-analysis. J Telemed Telecare 2019; 25: 389-401
65 Skinner R. et al. A systematic review with meta-analyses of text message-delivered behaviour change interventions for weight loss and weight loss maintenance. Obes Rev 2020; 21: e12999
66 Villinger K. et al. The effectiveness of app-based mobile interventions on nutrition behaviours and nutrition-related health outcomes: A systematic review and meta-analysis. Obes Rev 2019; 20: 1465-1484
67 Ross Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. Obes Rev 2012; 13: 509-517
68 Dombrowski SU. et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ (Clinical research ed.) 2014; 348: g2646-g2646
69 Peirson L. et al. Strategies for weight maintenance in adult populations treated for overweight and obesity: a systematic review and meta-analysis. CMAJ open 2015; 3: E47-E54
70 Varkevisser RDM. et al. Determinants of weight loss maintenance: a systematic review. Obes Rev 2019; 20: 171-211